Why the study?
Does picotamide reduce mortality and major cardiovascular events compared to aspirin in adults with type 2 diabetes and peripheral arterial disease?
Does picotamide reduce mortality and major cardiovascular events compared to aspirin in adults with type 2 diabetes and peripheral arterial disease?
Picotamide significantly reduces 2-year overall mortality compared to aspirin in patients with type 2 diabetes and peripheral arterial disease.
No takes yet. Share an insight, caveat, or question.
Picotamide may be preferred to aspirin for mortality reduction in type 2 diabetes with peripheral arterial disease; extends randomized evidence for targeted antiplatelet strategies in this population.
Coccheri et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: